BiotechTube
Home/Pipeline/Synergies with Antibodies

Synergies with Antibodies

Not Specified

ResearchResearch

Key Facts

Indication
Not Specified
Phase
Research
Status
Research
Company
Phio Pharmaceuticals

About Phio Pharmaceuticals

Phio Pharmaceuticals is a clinical-stage biotech company leveraging its proprietary INTASYL self-delivering siRNA platform to develop next-generation immuno-oncology therapies. Founded on Nobel laureate Craig Mello's RNAi discovery, the company has pivoted from discovery to development, advancing lead candidates PH-762 (PD-1 silencer) and PH-894 (BRD4 silencer) through early clinical trials. Its strategy focuses on overcoming delivery challenges in RNAi to enhance immune cell function and directly attack tumors, aiming to create synergistic treatments for cancers like cutaneous squamous cell carcinoma and melanoma.

View full company profile

Therapeutic Areas

OncologyImmuno-Oncology

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved